9月15日，昂利康跌5.02%，截至发稿，报43.17元/股，成交6.56亿元，换手率8.04%，总市值87.09亿 元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，浙江昂利康制药股份有限公司位于浙江省嵊州市嵊州大道北1000号，成立日期2001年12月30 日，上市日期2018年10月23日，公司主营业务涉及从事化学原料药及制剂的研发、生产和销售。主营业 务收入构成为：制剂43.46%，原料药39.82%，特色中间体12.44%，其他3.72%，药用辅料0.56%。 责任编辑：小浪快报 从昂利康十大流通股东角度 工银前沿医疗股票A（001717）基金经理为赵蓓。 截至发稿，赵蓓累计任职时间10年305天，现任基金资产总规模164.25亿元，任职期间最佳基金回报 263.6%， 任职期间最差基金回报-25.29%。 数据显示，工银瑞信基金旗下1只基金位居昂利康十大流通股东。工银前沿医疗股票A（001717）二季 度新进十大流通股东，持有股数380.22万股 ...

华富健康文娱灵活配置混合A（001563）基金经理为廖庆阳。 截至发稿，廖庆阳累计任职时间3年308天，现任基金资产总规模7402.7万元，任职期间最佳基金回报 42.84%， 任职期间最差基金回报-0.06%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 9月12日，昂利康涨5.01%，截至发稿，报43.39元/股，成交4.48亿元，换手率5.72%，总市值87.53亿 元。 资料显示，浙江昂利康制药股份有限公司位于浙江省嵊州市嵊州大道北1000号，成立日期2001年12月30 日，上市日期2018年10月23日，公司主营业务涉及从事化学原料药及制剂的研发、生产和销售。主营业 务收入构成为：制剂43.46%，原料药39.82%，特色中间体12.44%，其他3.72%，药用辅料0.56%。 从基金十大重仓股角度 数据显示，华富基金旗下1只基金重仓昂利康。华富健康文娱灵活配置混合A（001563）二季度持有股 数15万股，占基金净值比例为7.52%，位居第二大重仓股。根 ...

证券之星消息，9月12日化学制药板块较上一交易日上涨0.78%，苑东生物领涨。当日上证指数报收于 3883.69，上涨0.22%。深证成指报收于12996.38，上涨0.13%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688513 | 苑东生物 | 58.88 | 11.33% | 6.01万 | | 3.39 Z | | 688428 | 诺诚健华 | 29.62 | 11.14% | 11.75万 | | 3.26亿 | | 688799 | 华纳药厂 | 63.95 | 10.05% | 7.48万 | | 4.56 乙 | | 002940 | 昂利康 | 44.90 | 8.66% | 14.57万 | | 6.24亿 | | 300436 | 广生堂 | 122.04 | 7.01% | 16.94万 | | 19.95 G | | 600521 | 三国思想 | 25.06 | 6.32% | 62.36万 | | 15.57亿 ...

8月26日，昂利康跌5.02%，截至发稿，报52.83元/股，成交8.97亿元，换手率8.70%，总市值106.57亿 元。 资料显示，浙江昂利康制药股份有限公司位于浙江省嵊州市嵊州大道北1000号，成立日期2001年12月30 日，上市日期2018年10月23日，公司主营业务涉及从事化学原料药及制剂的研发、生产和销售。主营业 务收入构成为：原料药48.60%，制剂35.57%，特色中间体13.01%，其他1.61%，药用辅料1.21%。 从基金十大重仓股角度 责任编辑：小浪快报 数据显示，建信基金旗下1只基金重仓昂利康。建信兴衡优选一年持有混合A（014781）二季度持有股 数4.28万股，占基金净值比例为2.82%，位居第五大重仓股。根据测算，今日浮亏损失约11.94万元。 建信兴衡优选一年持有混合A（014781）成立日期2022年6月21日，最新规模4364.84万。今年以来收益 48.06%，同类排名602/8194；近一年收益59.06%，同类排名1726/7962；成立以来收益14.97%。 建信兴衡优选一年持有混合A（014781）基金经理为马牧青。 截至发稿，马牧青累计任职时间3年243天， ...

1.5亿元首付加码创新药，聚焦CD47「明星」靶点 8月27日晚，昂利康(002940.SZ)披露半年度报告。2025年上半年实现营业收入7.24亿元，归母净利润 6592.51万元，同比均小幅下滑。然而与短期财务数据表现不同，围绕创新药研发的战略布局，市场对 公司发展前景却抱有较高的认可度。 与中报同期，公司同步披露了《关于签署战略合作之授权许可协议的公告》及《关于拟投资建设年产 8000吨阿莫西林、2000吨氨苄西林项目的公告》，公司正加速从以原料药为主的制药企业，转型为纵深 布局的「仿创协同」药企。与此同时，公司还披露了半年度利润分配方案，拟每10股派发现金股利1元 (含税)，预计派发总额达1961.08万元，充分传递出公司对现金流的信心。 在深化创新药布局，寻求业务增长点的同时，昂利康也在持续强化原料药领域的行业竞争力，筑牢公司 业绩根基。据同步披露公告，公司拟以自有资金及银行贷款投资3.89亿元，在浙江嵊州新建「年产8000 吨阿莫西林、2000吨氨苄西林建设项目」。 公告指出，此次项目建设周期两年，建成后除扩充了年产8000吨阿莫西林及2000吨氨苄西林产品产能 外，还将形成年产3165吨氯化铵、 ...

Group 1 - The stock price of Anglikon Pharmaceuticals dropped by 5.06% to 43.49 CNY per share, with a trading volume of 363 million CNY and a turnover rate of 4.37%, resulting in a total market capitalization of 8.773 billion CNY [1] - Anglikon Pharmaceuticals, established on December 30, 2001, and listed on October 23, 2018, is primarily engaged in the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikon Pharmaceuticals includes formulations at 43.46%, raw materials at 39.82%, specialty intermediates at 12.44%, other products at 3.72%, and pharmaceutical excipients at 0.56% [1] Group 2 - In the second quarter, Invesco Great Wall Fund held 48,000 shares of Anglikon, representing 4.95% of the fund's net value, making it the eighth largest holding [2] - The Invesco Great Wall Medical Industry Stock A fund, established on January 24, 2025, has a latest scale of 15.9413 million CNY and has achieved a return of 72.54% since inception [2] - The fund manager, Qiao Haiying, has a tenure of 10 years and 361 days, with total assets under management of 327 million CNY, achieving a best return of 147.43% and a worst return of -11.7% during the tenure [2]

Company Overview - Zhejiang Angli Kang Pharmaceutical Co., Ltd. is located at 1000 North Shengzhou Avenue, Shengzhou City, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018 [1] - The company's main business involves the research, production, and sales of chemical raw materials and formulations [1] Revenue Composition - The revenue composition of the company is as follows: formulations account for 43.46%, raw materials 39.82%, specialty intermediates 12.44%, others 3.72%, and pharmaceutical excipients 0.56% [1] Stock Performance - On September 4, the stock price of Angli Kang fell by 5.06%, closing at 43.49 CNY per share, with a trading volume of 363 million CNY and a turnover rate of 4.37%, resulting in a total market capitalization of 8.773 billion CNY [1] Fund Holdings - According to data, one fund under Lobo Mai holds a significant position in Angli Kang, specifically the Lobo Mai China Healthcare Equity Fund A (020142), which held 35,500 shares, representing 4.5% of the fund's net value, making it the eighth largest holding [2] - The fund has a current size of 14.5216 million CNY and has achieved a year-to-date return of 46.7%, ranking 327 out of 4222 in its category [2] Fund Manager Performance - The fund manager of Lobo Mai China Healthcare Equity Fund A is Li Tao, who has been in the position for 1 year and 254 days, with total assets under management of 29.2458 million CNY [3] - During Li Tao's tenure, the best fund return was 17.87%, while the worst return was 16.66% [3]

Overview - The market for Doxofylline tablets in China is steadily growing, driven by a large population of asthma patients, with sales expected to reach 125 million yuan in 2024, representing a year-on-year growth of 4.17% [1][8] - Public medical institutions account for over 90% of the sales, and the aging population is expected to further increase demand for Doxofylline tablets [1][8] Industry Chain - The upstream of the Doxofylline tablet industry includes raw materials, excipients, packaging materials, and pharmaceutical equipment; the midstream consists of production enterprises; and the downstream includes public medical institutions, physical pharmacies, e-commerce channels, and end consumers [4][5] Market Demand - The demand for Doxofylline tablets is significantly influenced by the procurement needs of public medical institutions, which are the primary sales channel due to the prescription nature of the drug [6] - As of the end of 2024, the number of medical institutions in China is projected to reach 1.092 million, a year-on-year increase of 2.0%, which will further expand the demand for Doxofylline tablets [6] Patient Demographics - The number of asthma patients in China is expected to reach 72.4 million in 2024, with a year-on-year growth of 4.32%, contributing to the increasing clinical demand for Doxofylline tablets [8] Competitive Landscape - The Doxofylline tablet market in China features both international companies and domestic firms, with local companies dominating the market. The competitive landscape is expected to evolve due to regulatory policies and procurement reforms [9][10] - Key domestic players include Fuan Pharmaceutical and Zhejiang Anglikang Pharmaceutical, with Fuan Pharmaceutical reporting a total revenue of 2.391 billion yuan and a gross profit margin of 52.96% in 2024 [10][11] Future Trends - The demand for Doxofylline tablets is anticipated to grow significantly in grassroots medical institutions as healthcare policies advance, leading to a downward trend in treatment accessibility [11] - Continuous implementation of volume-based procurement policies will encourage companies to enhance production efficiency and cost control, potentially increasing market concentration and optimizing the competitive landscape [11]

每经头条（nbdtoutiao）——个人消费贷贴息明日开闸！贷30万元最多可享贴息3000元，一文读懂→ （记者 王晓波） 2025年1至6月份，昂利康的营业收入构成为：医药制造业占比100.0%。 截至发稿，昂利康市值为99亿元。 每经AI快讯，昂利康（SZ 002940，收盘价：49元）9月1日晚间发布公告称，截至2025年8月31日，公司 通过回购专用证券账户以集中竞价交易方式累计回购股份数量约为360万股，约占公司总股本的 1.78%，最高成交价为17元/股，最低成交价为12.17元/股，交易总金额约5000万元。 ...

浙江昂利康制药股份有限公司 关于回购公司股份的进展公告 证券代码：002940 证券简称：昂利康 公告编号：2025-068 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召 开第四届董事会第六次会议，审议通过了《关于回购公司股份方案的议案》，同 意公司使用自有资金及股票回购专项贷款以集中竞价的方式回购公司部分已发 行的社会公众股份，回购的股份将用于后续员工持股计划或者股权激励。本次回 购股份的资金总额不低于人民币5,000万元（含）且不超过人民币7,000万元（含）， 回购价格不超过人民币 21.07 元/股（含）。具体回购股份的数量以公司实际回购 的股份数量为准。本次回购股份的实施期限为自董事会审议通过本次回购股份方 案之日起不超过 12 个月。具体内容详见公司于 2024 年 11 月 5 日、2024 年 11 月 8 日在指定信息披露媒体《证券时报》及巨潮资讯网（www.cninfo.com.cn）上 刊载的《关于回购公司股份方案暨收到<贷款承诺书>的公告》（公告编号： ...